MIRM logo

Mirum Pharmaceuticals Inc. (MIRM)

$91.95

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MIRM

Market cap

$6.00B

EPS

-15.46

P/E ratio

--

Price to sales

9.04

Dividend yield

--

Beta

0.758556

Price on MIRM

Previous close

$91.58

Today's open

$91

Day's range

$89.27 - $92.31

52 week range

$63.23 - $130

Profile about MIRM

CEO

Christopher Peetz

Employees

433

Headquarters

Foster City, CA

Exchange

NASDAQ Global Market

Shares outstanding

65282044

Issue type

Common Stock

MIRM industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MIRM

AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity

During this quarter, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index as the market rewarded the quality characteristics our process emphasizes. We benefited most from our holdings in the Information Technology, Financials, and Consumer Staples sectors, while positioning in the Industrials, Health Care, and Consumer Discretionary sectors offset part of the gain. Each of our largest contributors was driven by company-specific fundamentals, including solid results and business momentum, and, in two cases, making acquisitions we viewed as strategically or financially attractive.

news source

Seeking Alpha • Nov 15, 2026

news preview

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

news source

Business Wire • Nov 12, 2026

news preview

MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

Mirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.

news source

Zacks Investment Research • Nov 11, 2026

news preview

Mirum's liver infection drug lowers virus levels in second late-stage study

Mirum Pharmaceuticals said on Tuesday its experimental treatment for hepatitis delta, ​a serious liver infection, led to ‌reduced virus and normal liver enzyme levels, meeting the main goal of a second ​late-stage study.

news source

Reuters • Nov 10, 2026

news preview

Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD.

news source

Business Wire • Nov 10, 2026

news preview

GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.

news source

Business Wire • Nov 5, 2026

news preview

Mirum Pharmaceuticals Q3 Earnings Call Highlights

Mirum Pharmaceuticals NASDAQ: MIRM reported third-quarter net product sales of $186 million and raised its full-year 2026 net product sales guidance to $715 million to $720 million, citing continued growth of LIVMARLI and its bile acid medicines as well as progress across its late-stage pipeline.

news source

MarketBeat • Nov 4, 2026

news preview

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Peter Radovich - COO & President Rob Myers - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Yesha Patel - Evercore ISI Institutional Equities, Research Division Kalpit Patel - Wolfe Research, LLC Ryan Deschner - Raymond James & Associates, Inc., Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Michael Ulz - Morgan Stanley, Research Division Lisa Walter - RBC Capital Markets, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Charles Wallace - H.C.

news source

Seeking Alpha • Nov 4, 2026

news preview

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update.

news source

Business Wire • Nov 3, 2026

news preview

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to earnings of $0.05 per share a year ago.

news source

Zacks Investment Research • Nov 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Mirum Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Mirum Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MIRM on M1